I think heres why things are looking up for now
S&P UPGRADES SHARES OF RESMED TO BUY FROM HOLD
RMD; $42.47
We see RMD poised to gain from Medicare's decision to expand coverage for CPAP devices for beneficiaries diagnosed with obstructed sleep apnea using home tests. Medicare thinks up to 4 million beneficiaries have OSA. We also believe its decision will sway private payers to follow suit, especially since Aetna recently permitted home tests. But we do not see sales impacted for 12-18 months, by which time we expect detailed guidelines to be available. On the good news, we raise our target PEG ratio from 1.5X to an above-peer 1.6X and our target price by $4 to $51. /P. Seligman
http://www.businessweek.com/investor/content/mar2008/pi20080314_343011.htm?campaign_id=yhoo
has rmd bottomed, page-2
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$36.66 |
Change
-0.940(2.50%) |
Mkt cap ! $22.38B | |||
| Open | High | Low | Value | Volume |
| $36.32 | $36.69 | $36.13 | $46.16M | 1.265M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 13944 | $36.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $36.71 | 12610 | 4 |
View Market Depth
| Last trade - 16.10pm 14/11/2024 (20 minute delay) ? |
| RMD (ASX) Chart |
